Q. Wei

发表

Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism

Hai-di Wu, L. Qin, Minglong Tang, 2019, Medicine.

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system

Feifei Wang, Xinan Wu, Q. Wei, 2022, Frontiers in Pharmacology.

Combination of D-dimer and simplified pulmonary embolism severity index to improve prediction of hospital death in patients with acute pulmonary embolism

Zikai Song, Hai-di Wu, L. Qin, 2020, The Journal of international medical research.

Long Noncoding RNA NEAT1 Promotes Myocardiocyte Apoptosis and Suppresses Proliferation Through Regulation of miR-129-5p.

L. Qin, Hong-yan Cao, Huan-Yu Zhou, 2019, Journal of cardiovascular pharmacology.

fast-start action pharmacokinetic and pharmacodynamic characteristics, and has an enhanced predictable anticoagulant effect with fewer drug-drug interactions. Based on randomized controlled trials and real-world clinical practice, rivaroxaban has also been recognized as a safe and effective anticoag

Zikai Song, Hai-di Wu, L. Qin, 2020 .

Association between systemic iron status and β-cell function and insulin sensitivity in patients with newly diagnosed type 2 diabetes

Yiting Huang, L. Qin, Yuxiao Li, 2023, Frontiers in Endocrinology.

Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US healthcare system.

P. Mease, J. Hadlock, M. Chiorean, 2023, medRxiv.

Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)

Zikai Song, Hai-di Wu, L. Qin, 2020, Experimental and therapeutic medicine.

Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system

P. Mease, J. Hadlock, S. Molani, 2023, medRxiv.